Clinical trials: Allogenic Transplant Patients
Mesenchymal Stem Cell Transplantation
Intraosseous Administration of Mesenchymal Stromal Cells for Patients With Graft Failure After Allo-HSCT
Multipotent mesenchymal stromal cells (MSCs) participate in the formation of bone marrow niches for hematopoietic stem cells. Donor MSCs can serve as a source of recovery for niches in patients with graft failure (GF) after…
- Trial name
- NCT03389919
- Testing
- MSC administration (intraosseal)
- Where
- Russia
- Volunteers
- 20 people
- Sponsor
- National Research Center for Hematology, Russia
Multiple Myeloma
Chemotherapy, Stem Cell Transplantation and Donor and Patient Vaccination for Treatment of Multiple Myeloma
Background: The mainstay of therapy for newly diagnosed multiple myeloma patients remains systemic chemotherapy. Although partial remissions of up to 60% are obtained with conventional regimens, multiple myeloma is essentially an…
- Trial name
- NCT00006184
- Testing
- Myeloma Immunoglobulin Idiotype Vaccine, Bortezomib, Cyclophosphamide
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Cancer Institute (NCI)
Acute Leukemia
A Retrospective Study on the Relationship Between Donor Leukocyte Telomere Length and Prognosis of Acute Leukemia Patients Treated With Allogeneic Hematopoietic Stem Cell Transplantation
This post hoc analysis included patients with acute leukemia who underwent allo-HSCT at the First Affiliated Hospital of Zhejiang University School of Medicine and Ruijin Hospital Shanghai Jiaotong University School of Medicine.
- Trial name
- NCT06076226
- Testing
- No intervention, observation study
- Where
- China
- Volunteers
- 2,500 people, healthy volunteers welcome
- Sponsor
- Zhejiang University
Patients Receiving Mismatched Allogeneic HCT
Multicenter Study of Peritransplantation Immunosuppression for Mismatched Hematopoietic Cell Transplantation After Reduced Intensity Conditioning
Feasibility and toxicity of peritransplantation immunosuppression with ATG, sirolimus, mycophenolate mofetil and rituximab in patients receiving mismatched allogeneic HCT after a reduced intensity conditioning regimen with…
- Trial name
- NCT01582048
- Testing
- immunosuppression
- Where
- 4 sites in Germany
- Volunteers
- 9 people
- Sponsor
- Prof. Dr. med. Wolfgang Bethge
Multiple Myeloma
Allo Transplant Followed by Lenalidomide and Sirolimus Maintenance in High-Risk Multiple Myeloma (MM)
One of the complications that can occur after a stem cell transplant is called graft versus host disease (GVHD). Another complication is that multiple myeloma may come back (relapse).
- Trial name
- NCT01303965
- Testing
- Sirolimus, Tacrolimus, Lenalidomide
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Sherif S. Farag
Graft Versus Host Disease
Chronic Graft-versus-Host Disease in the Oral Cavity of Patients Following Allogeneic Hematopoietic Stem Cell Transplant and Including Healthy Controls
Background: This study follows people who have had, or will soon have, a transplant using stem cells from another person. This is known as an allogeneic hematopoietic stem cell transplant (HSCT).
- Trial name
- NCT03602599
- Where
- United States
- Volunteers
- 190 people
- Sponsor
- National Institute of Dental and Craniofacial Research (NIDCR)
Leukemia, Neutropenia
SWOG-9400 Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Previously Untreated Acute Lymphocytic Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with bone marrow transplantation may allow the doctor to give higher doses of…
- Conditions
- Leukemia, Neutropenia, Thrombocytopenia
- Trial name
- NCT00002665
- Testing
- asparaginase, cyclophosphamide, cytarabine
- Where
- 83 sites in United States
- Volunteers
- 50 people
- Sponsor
- SWOG Cancer Research Network
Secondary Acute Myeloid Leukemia Evolving From MDS, Allogeneic Hematopoietic Stem Cell Transplantation
G-CSF+DAC+BUCY vs G-CSF+DAC+BF Conditioning Regimen for Secondary Acute Myeloid Leukemia Undergoing Allo-HSCT
Allo-HSCT is the most effective way to cure sAML patients. At present, the best conditioning regimen for sAML patients undergoing allo-HSCT remains in discussion.
- Conditions
- Secondary Acute Myeloid Leukemia Evolving From MDS, Allogeneic Hematopoietic Stem Cell Transplantation, Conditioning
- Trial name
- NCT05449899
- Testing
- Granulocyte Colony-Stimulating Factor(G-CSF), Decitabine (DAC), Busulfan (BU)
- Where
- China
- Volunteers
- 232 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Acute Myeloid Leukemia, Myelodysplastic Syndrome
TevaGastrim for Stem Cell Mobilization Sibling Donors
The aim of this study is to evaluate the efficacy of TevaGastrim which is a biosimilar version of Filgrastim recombinant human G-CSF (G-CSF) in mobilizing sufficient number of stem cells from normal sibling donors for allogeneic…
- Trial name
- NCT01542944
- Testing
- TevaGastrim
- Where
- Israel
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Sheba Medical Center
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Adult Acute Lymphoblastic Leukemia in Remission
Vaccine Therapy in Reducing the Frequency of Cytomegalovirus Events in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant
This randomized phase II trial studies how well vaccine therapy works in reducing the frequency of cytomegalovirus severe infections (events) in patients with hematologic malignancies undergoing donor stem cell transplant.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Hodgkin Lymphoma
- Trial name
- NCT02396134
- Testing
- CMVpp65-A*0201 peptide vaccine, Laboratory Biomarker Analysis
- Where
- 5 sites in United States
- Volunteers
- 61 people
- Sponsor
- City of Hope Medical Center
Leukemia, Stem Cell Transplantation
Study of the Trifunctional Antibody FBTA05 and Donor Lymphocyte Infusion in B-cell Lymphoma After Allogeneic Stem Cell Transplantation
This study is an investigator driven, open-label, non-randomized, uncontrolled, dose escalating Phase I/II study evaluating the safety and preliminary efficacy of the trifunctional bispecific antibody FBTA05 in combination with…
- Trial name
- STP-LYM-01 (NCT01138579)
- Testing
- FBTA05
- Where
- Germany
- Sponsor
- Technical University of Munich
Allogenic Hematopoietic Cell Transplant, CAR-T Therapy
COVID-19 Vaccine in Patients After Allogeneic HCT, CAR-T Therapy and With Primary Immune Deficiency
The corona pandemic is a continuing global challenge due to Corona Virus 2019 (COVID-19). The purpose of the study is to confirm the accepted hypothesis from the recommendations of The European Society for Blood and Marrow…
- Conditions
- Allogenic Hematopoietic Cell Transplant, CAR-T Therapy, Primary Immunodeficiency
- Trial name
- NCT04724642
- Where
- Israel
- Volunteers
- 110 people
- Sponsor
- Tel-Aviv Sourasky Medical Center
Acute Myeloid Leukemia
Tagraxofusp to Eradicate Measurable Residual Disease in Patients With Acute Myeloid Leukemia
This phase Ib/II trial tests the safety of tagraxofusp when given with or without azacitidine in patients with acute myeloid leukemia in remission with measurable residual disease who will undergo allogeneic hematopoietic cell…
- Trial name
- NCT05720988
- Testing
- Azacitidine, Tagraxofusp-erzs
- Where
- 2 sites in United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Hematopoietic/Lymphoid Cancer
Brentuximab Vedotin After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
This phase I/II trial studies the side effects and best way to give brentuximab vedotin and to see how well it works after donor stem cell transplant in treating patients with hematologic malignancies.
- Trial name
- NCT01620229
- Testing
- brentuximab vedotin, laboratory biomarker analysis, pharmacological study
- Where
- United States
- Sponsor
- Fred Hutchinson Cancer Center
Central Nervous System Leukemia, Allogeneic Hematopoietic Stem Cell Transplantation
Clinical Study of TBF Regimen in Allo-HSCT in Patients With CNS Leukemia
Central nervous system (CNS) leukemia is a poor prognostic factor for allogeneic hematopoietic stem cell transplantation (allo-HSCT).
- Trial name
- NCT05667402
- Testing
- TBF regimen, modified BuCY2 regimen
- Where
- China
- Volunteers
- 50 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Graft-versus-Host Disease
Lenalidomide (Revlimid®) as Second Line Therapy in Patients With Chronic Graft-Vs-Host Disease (GVHD)
The goal of this clinical research study is to learn if Revlimid® (lenalidomide), along with standard-of-care steroid treatment you are already receiving, can help to control Chronic Graft-Versus-Host Disease (cGVHD).
- Trial name
- NCT00675441
- Testing
- Lenalidomide
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- M.D. Anderson Cancer Center
Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
Chemotherapy Plus Bone Marrow Transplantation in Treating Patients With Refractory Non-Hodgkin's Lymphoma, Hodgkin's Disease, or Multiple Myeloma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining bone marrow transplantation with chemotherapy may allow doctors to give higher doses of…
- Trial name
- NCT00002552
- Testing
- filgrastim, sargramostim, carmustine
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Acute Myelogenous Leukemia
Decitabine and Vaccine Therapy for Patients With Relapsed AML Following Allogeneic Stem Cell Transplantation
Patients with Acute Myelogenous Leukemia (AML) who relapse after an allogeneic stem cell transplant cell receive decitabine to up regulate cancer antigen expression, followed by a donor lymphocyte infusion and an autologous…
- Trial name
- AML (NCT01483274)
- Testing
- Vaccine
- Where
- United States
- Sponsor
- University of Louisville
Multiple Myeloma and Plasma Cell Neoplasm
Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by…
- Trial name
- NCT00014508
- Testing
- sargramostim, cyclophosphamide, cyclosporine
- Where
- 12 sites in United States
- Sponsor
- Eastern Cooperative Oncology Group
Graft Versus Host Disease, Systemic Scleroderma
Imatinib and Rituximab in Treating Cutaneous Sclerosis in Patients With Chronic Graft-Versus-Host Disease
This randomized phase II trial is evaluating how well imatinib mesylate works compared to rituximab in treating cutaneous sclerosis in patients with chronic graft- versus-host disease (GVHD).
- Trial name
- NCT01309997
- Testing
- imatinib mesylate, rituximab
- Where
- 10 sites in United States
- Volunteers
- 72 people
- Sponsor
- Lee, Stephanie